Retzius‐sparing versus standard robot‐assisted laparoscopic prostatectomy: A two‐year patient‐reported and oncological assessment
The Prostate · 2025
DOI: 10.1002/pros.24807 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Prostate, 2025. Verfasst von Romain Diamand und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium. Hauptthemen laut MEDLINE: Prostatectomy, Robotic Surgical Procedures, Prostatic Neoplasms, Patient Reported Outcome Measures. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Purpose
To evaluate the two‐year functional and oncological outcomes of Retzius‐sparing robot‐assisted laparoscopic prostatectomy (rsRALP) and standard approach (sRALP).
Methods
A total of 200 consecutive patients who underwent either sRALP (n = 100) or rsRALP (n = 100) for clinically localized PCa at a single referral European center between 2015 and 2020 were identified from a prospectively cohort, as part of the Belgian Cancer Registry. Primary outcomes included functional outcomes and quality of life (QoL) using validated patient‐reported outcome measures (PROMs) assessed at 1‐, 3‐, 12‐, and 24‐months post‐surgery. Secondary outcomes comprised oncological outcomes reported as positive surgical margins (PSM) and 5‐year biochemical recurrence (BCR). Kaplan‐Meier analysis with log‐rank test and multivariable Cox regression were used.
Results
The median follow‐up was 60 months. No significant differences were observed between the surgical approaches in terms of patient and tumor characteristics. Urinary function and QoL were significantly better at each follow‐up period (all p ≤ 0.01) with rsRALP, while sexual function was not significantly different 12 months after surgery. No significant difference in positive surgical margins rate was observed between surgical approaches (31% vs 32%, p = 0.9). Retzius‐sparing RALP was associated with longer PSM lengths (5 mm vs 2.5 mm, p = 0.02), a higher multifocality rate (34% vs. 13%, p < 0.001), more occurrences in organ‐confined disease (59% vs. 39%, p < 0.001) and at anterior locations (37% vs. 16%, p = 0.05). Five‐year BCR‐free survival was not significantly different, and surgical approach was not a predictor of BCR.
Conclusions
The rsRALP approach significantly improves both early and short‐term urinary function and QoL compared to sRALP. Despite being associated with worse PSM characteristics, no significant decrease in BCR‐free survival was observed with rsRALP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Jules Bordet Institute-Erasme Hospital, Hôpital Universitaire de Bruxelles, Université Libre de Bruxelles, Brussels, Belgium.
- Department of Urology, Europe Hospitals, Ste-Elisabeth, Brussels, Belgium.
ORCID-Profile: Romain Diamand, Georges Mjaess
Zitieren
APA
Diamand, R., Bernard, P. L., Mjaess, G., Benijts, J., Assenmacher, C., & Assenmacher, G. (2025). Retzius‐sparing versus standard robot‐assisted laparoscopic prostatectomy: A two‐year patient‐reported and oncological assessment. The Prostate. https://doi.org/10.1002/pros.24807
Vancouver
Diamand R, Bernard PL, Mjaess G, Benijts J, Assenmacher C, Assenmacher G. Retzius‐sparing versus standard robot‐assisted laparoscopic prostatectomy: A two‐year patient‐reported and oncological assessment. The Prostate. 2025. doi:10.1002/pros.24807
BibTeX
@article{Diamand2025,
author = {Diamand, Romain and Bernard, Pierre-Loup and Mjaess, Georges and Benijts, Jan and Assenmacher, Christophe and Assenmacher, Grégoire},
title = {Retzius‐sparing versus standard robot‐assisted laparoscopic prostatectomy: A two‐year patient‐reported and oncological assessment},
journal = {The Prostate},
year = {2025},
doi = {10.1002/pros.24807}
}
EUVIMED